Abstract
Background Previous studies have proved that viral infection might have potential associations with differentiated thyroid cancer. COVID-19 has spread to hundreds of millions of individuals since Dec 2019. This study aimed to investigate the common pathogenic mechanisms of differentiated thyroid cancer and SARS-CoV-2 infection in thyroid tissues.
Methods The proteomic profiles of COVID-19 and differentiated thyroid cancer were downloaded from iProx database and were analyzed for differentially expressed proteins. After the common proteins were identified using the Venn diagram, gene ontology and pathway enrichment analysis were performed. Subsequently, a protein-protein interaction network was constructed and hub genes were identified with eight algorithms. The diagnostic performance of hub genes was tested with the receiver operator characteristics curve. The associations between hub genes and diseases were evaluated with the Comparative Toxicogenomics Database.
Results Forty-nine common differentially expressed proteins were identified. Functional analysis revealed that the metabolism and transport of lipid and cholesterol and coagulation process were the main common biological activities affected by the two diseases. In addition, twelve genes, including AGT, AHSG, APOA2, APOM, C3, GC, ITIH2, KNG1, SERPINA1, SERPINC1, TF and TTR, were identified as the hub genes. These genes could serve as diagnostic markers for COVID-19 and differentiated thyroid cancers.
Conclusion The current study revealed common pathogenic mechanisms of COVID-19 and differentiated thyroid cancer. The concomitant infection of SARS-CoV-2 might exert adverse effects on patients with thyroid cancers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the grants from Beijing Xisike Clinical Oncology Research Foundation (Y-SY201901-0189), the Fundamental Research Funds for the Central Universities (2042019kf0229), the Science and Technology Major Project of Hubei Province (Next-Generation AI Technologies) (2019AEA170).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at iProx database (IPX0001444000 & IPX0002393000).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The two proteomic profiles can be downloaded from iProx database (IPX0001444000 & IPX0002393000). Supplementary figures and data files were deposited in Mendeley database (DOI: 10.17632/5cg2dmz5nb.2).
https://www.iprox.cn//page/SCV017.html?query=IPX0001444000
